Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LW402 + methotrexate
- Development stage
- Phase 2
- Lead developer
- Shanghai Longwood Biopharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
LW402 + methotrexate is a combination drug regimen under investigation for the treatment of adults with active rheumatoid arthritis. **Methotrexate** is a well-established antimetabolite and folate antagonist that inhibits several enzymes necessary for nucleotide synthesis, resulting in anti-inflammatory and anti-neoplastic effects. It is a standard treatment for rheumatoid arthritis and related autoimmune and neoplastic disorders. **LW402** is an investigational oral small molecule, being studied specifically in combination with methotrexate, for its potential to improve disease outcomes in moderately to severely active rheumatoid arthritis patients who have been on stable methotrexate doses[5]. The precise mechanism of action of LW402 has not been disclosed in public sources, but clinical trials are focused on its use as an adjunct to methotrexate therapy. The combination is administered orally.
- Other names
- LW402 + methotrexate
02
Targets
DHFR (Dihydrofolate reductase)JAK1 (Janus kinase 1)JAK2 (Janus kinase 2)JAK3 (Janus kinase 3)TYK2 (Tyrosine kinase 2)TS (Thymidylate synthase)ATIC (Aminoimidazole carboxamide ribonucleotide transformylase)IL1R1 (Interleukin-1 Receptor Type 1)
Beyond the preview
Go deeper on LW402 + methotrexate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LW402 + methotrexate.